Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 12-Month High – Time to Buy?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $114.60 and last traded at $114.7810, with a volume of 282797 shares trading hands. The stock had previously closed at $109.60.

Wall Street Analyst Weigh In

DNTH has been the topic of several analyst reports. Truist Financial boosted their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Wedbush raised their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $124.27.

Dianthus Therapeutics Stock Performance

The company has a market capitalization of $6.34 billion, a price-to-earnings ratio of -27.94 and a beta of 1.22. The business has a 50 day moving average price of $97.47 and a 200-day moving average price of $82.85.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. As a group, equities analysts predict that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Insider Transactions at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president directly owned 31,249 shares of the company’s stock, valued at $3,157,086.47. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Anne Mcgeorge sold 7,750 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $109.01, for a total transaction of $844,827.50. Following the sale, the director owned 1,250 shares of the company’s stock, valued at approximately $136,262.50. The trade was a 86.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 284,306 shares of company stock valued at $29,289,369. Corporate insiders own 3.02% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

A number of large investors have recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in shares of Dianthus Therapeutics in the second quarter valued at $27,000. First Horizon Corp bought a new position in shares of Dianthus Therapeutics during the 1st quarter worth $32,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics during the 4th quarter worth $40,000. EFG International AG purchased a new stake in Dianthus Therapeutics in the 2nd quarter worth about $49,000. Finally, Russell Investments Group Ltd. purchased a new stake in Dianthus Therapeutics in the 3rd quarter worth about $64,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.